Chemistry:Silevertinib

From HandWiki

Silevertinib is an investigational new drug that is being evaluated by Black Diamond Therapeutics for the treatment of glioblastoma and non-small cell lung cancer.[1] It is a EGFR protein tyrosine kinase inhibitor.[1][2]

References

  1. ↑ 1.0 1.1 "Silevertinib". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800061315. 
  2. ↑ "Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR-Mutant Lung Cancer". Cancers (Basel) 17 (17): 2791. August 2025. doi:10.3390/cancers17172791. PMID 40940888. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Silevertinib&oldid=4582533"